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ABSTRACT
Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions
(RBCT). Transfusions may cause iron-related toxicity and mortality, influencing outcome after
allogeneic HSCT. This prospective non-interventional study evaluated 222 MDS and CMML
patients undergoing HSCT. Overall survival (OS), relapse-free survival (RFS), non-relapse mortality
(NRM), and relapse incidence (RI) at 36 months were 52%, 44%, 25%, and 31%, respectively.
Age, percentage of marrow blasts and severe comorbidities impacted OS. RFS was significantly
associated with RBCT burden prior to HSCT (HR: 1.7; p¼ .02). High ferritin levels had a significant
negative impact on OS and RI, but no impact on NRM. Administration of iron chelation therapy
prior to HSCT did not influence the outcome, but early iron reduction after HSCT (started before
6 months) improved RFS significantly after transplantation (56% in the control group vs. 90% in
the treated group, respectively; p¼ .04). This study illustrates the impact of RBCT and related
parameters on HSCT-outcome. Patients with an expected prolonged survival after transplant-
ation may benefit from early iron reduction therapy after transplantation.
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Introduction
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the most potent curative therapeutic option in
patients with myelodysplastic syndromes (MDS) [1]. Due
to high treatment-related morbidity and mortality, com-
bined with a high relapse risk, the current long-term
overall survival rate is around 35% [2–4]. Non-relapse
mortality (NRM) has decreased after the introduction of
reduced intensity regimens (RIC) for the elderly and
more frail patients with MDS [5,6]. Many parameters
such as age, comorbidity, advanced disease stage, and
cytogenetic risk category according to the (revised)-
International Prognostic Scoring system (IPSS-R) have
been reported to impact treatment outcome [4,7–10].
Around 80% of patients with MDS present with anemia
and many of these patients receive multiple red blood
cell transfusions (RBCT) during the course of their dis-
ease [11]. RBCT and associated iron overload may cause
toxicity and mortality, and influence outcome after
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HSCT [12–15]. Most studies are retrospective and selec-
tion bias and lack of detailed data about interventions,
outcome, and potentially confounding risk factors might
have influenced conclusions.
The Chronic Malignancies Working Party (CMWP) of
the EBMT performed a large prospective, non-interven-
tional study to evaluate prognostic pre-transplant fac-
tors in MDS and chronic myelomonocytic leukemia
(CMML). The primary objective of this study was to
evaluate the relation between iron toxicity and treat-
ment-related mortality after allogeneic HSCT in adult
MDS and CMML patients. We excluded patients
treated with intensive chemotherapy from this study,
because previous intensive chemotherapy is expected
to have an impact on important pre-HSCT co-variables,
including advanced stages of disease (relapsed or
refractory), more co-morbid conditions and poorer
general condition. This approach is expected to be
associated with a reduced pretreatment related mor-
bidity, and a reduction of the interval between diag-
nosis and HSCT. Secondary objectives were (i)
description of treatment outcomes defined by NRM,
OS, relapse incidence (RI) and relapse-free survival
(RFS); (ii) impact of RBCT and surrogate iron markers
that may reflect iron burden on treatment outcome.
The final objective was to evaluate the impact of iron
reduction therapy prior and post HSCT on the out-
come after HSCT.
Patients and methods
Two hundred twenty-two adult (age 18 years at
HSCT) patients with de-novo MDS, AML-MDS with
20–30% marrow blasts (formerly RAEBt) or patients
with CMML who received upfront HSCT after bone
marrow ablative or reduced intensity regimens were
included prospectively between January 2009 and
January 2014. Patients had an ECOG performance sta-
tus between 0 and 2. Exclusion criteria included previ-
ous intensive anti-leukemic chemotherapy, patients
with juvenile CMML, patients with therapy-related
MDS, AML, or CMML after treatment with immunosup-
pressive or cytotoxic treatment for a non-myeloid
malignancy, patients who had received auto-HSCT,
candidates for cord blood HSCT or syngeneic HSCT,
inadequate renal function (ECC <60ml/min and/or
creatinine >2.5 times upper limit of normal value),
inadequate hepatic function (transaminases >2.5 times
upper limit of normal value), history of seizures, preg-
nancy, and women of child-bearing potential and not
using adequate contraceptives, uncontrolled hyperten-
sion. The research was conducted according to the
Declaration of Helsinki and written informed consent
was obtained from each participating patient. Trial
registered at Clinicaltrial.gov Identifier: 842205547.
Retrospective data were collected by survey at diag-
nosis, and prospectively at transplantation and 6 weeks,
100 days, 6 months, 1 year, and annually thereafter.
Missing data were collected by follow-up surveys. Based
on the study objectives the following variables were col-
lected: age, gender, comorbidities, WHO classification,
cytogenetic characteristics according to IPSS-R, number
of transfusions, ferritin levels, hemoglobin levels, C-react-
ive protein (CRP), donor type, female-donor/male recipi-
ent vs. other combinations, interval diagnosis, and
HSCT, intensity of HSCT conditioning, acute and chronic
graft vs. host disease (GvHD), and data concerning treat-
ment with iron chelation or phlebotomy.
Primary end-points were overall survival (OS),
relapse-free survival (RFS), relapse incidence (RI), and
non-relapse mortality (NRM), evaluated at 36 months
after transplant. The median follow-up was estimated
using the reverse Kaplan–Meier method. Additionally,
acute GvHD grade I–II and III–IV, and limited and exten-
sive chronic GvHD were evaluated at 100 days and
36 months after transplant, respectively. OS and RFS
were estimated using the Kaplan–Meier product limit
estimation method, and differences in subgroups were
assessed by the Log-Rank test. Cumulative incidences
of relapse and NRM, were analyzed in a competing risks
framework. The cumulative incidences of acute GvHD
grade I–II and III–IV were estimated as competing risks,
considering as competing for event death before
aGvHD. The cumulative incidences of limited and
extensive cGvHD were estimated equivalently.
Subgroup differences were assessed by Gray’s test. Cox
proportional hazards regression was used to assess the
impact of potential risk factors in univariable and multi-
variable analyses. Multivariable analyses of RI and NRM
were performed using Cox cause-specific hazards mod-
els. The impact of post-transplant iron reduction ther-
apy was investigated using landmark analyses at 6, 12
and 24 months. The landmark population was defined
as patients alive (event¼death) and event-free
(event¼death and/or relapse) at the respective land-
mark time points. All p values were two-sided and
p< .05 was considered significant.
Results
Demographic and transplantation data
The study included 181 patients with MDS, 16 patients
with AML-MDS, and 25 patients with CMML from 29
European transplant centers (for details, see Table 1).
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The median age was 59 years (range 19–76 years).
WHO-classification at time of transplantation resulted
in 20 patients with RA/RARS, 36 with RCMD/RCMD-RS,
1 with 5q-, 50 with RAEB-1, 74 with RAEB-2, 25 with
CMML, and 16 with AML-MDS. In total, 70% of the
patients had received RBCT prior to HSCT. Median
number of RBC units transfused before transplant-
ation: 12 units (range: 1–146 units); median ferritin lev-
els: 700 ng/ml (range 8–9033 ng/ml). Median interval
between diagnosis and HSCT was 10 months (range
1–128 months). Time between diagnosis and HSCT
was <6 months for 56 patients and 6 months for
166 patients. A total of 99 patients received standard
conditioning (MAC) and 123 received a reduced
intensity (RIC) regime. After conditioning, 70 patients
received stem cells from a sibling, 4 from a mis-
matched relative, and 148 patients from an unrelated
donor. The incidence of acute GvHD grade I–II and
grade III–IV at 100 days was 1% (25–37%) and 14%
(9–18%), respectively. The incidence of limited or
extensive chronic GvHD at 36 months was 47%
(40–54%) and 20% (15–26%), respectively.
Univariable analysis of relevant factors on
primary end points
The median follow-up of the 222 registered patients
after HSCT was 39 months with 95% confidence
Table 1. Demographic data and estimates of survival outcomes and cumulative incidences.
N OS NRM RI RFS
All patients 222 52% (45–59%) 25% (19–32%) 31% (24–37%) 44% (37–51%)
Median age (95% CIa) / HR 59.3 (52.2–64.4) 1.4 (1.1–1.8) (0.002) 1.4 (1.0–1.8) (0.05) 1.3 (1.0–1.7) (0.07) 1.4 (1.1–1.8) (0.002)
Co-morbidities: overall p value .02 .1 .6 .03
No 126 (57%) 57% (47–67%) 21% (14–29) 31% (22–39) 48% (39–58%)
Mild/moderate 62 (28%) 53% (40–66%) 26% (14–37) 26% (15–38) 48% (35–61%)
Severe 34 (15%) 33% (16–49%) 40% (23–57) 37% (20–54) 23% (8–37%)
WHO at HSCTb: overall p value .002 .5 <.001 <.001
RA/RARS/del5q/RCMD(RS) 57 (26%) 73% (60–85%) 21% (10–32) 7% (0–14%) 72% (60–84%)
RAEB-1/RAEB-2 124 (56%) 49% (39–58%) 28% (20–37) 34% (25–43) 38% (28–47%)
AML-MDS 16 (7%) 15% (0–34%) 25% (4–46) 69% (46–91) 6% (0–18%)
CMML 24 (11%) 49% (27–72%) 17% (2–33) 42% (22–61) 41% (21–61%)
Cytogenetic subgroups:
overall p value
.8 .5 1 .8
very good/good 120 (58%) 51 (41–61%) 30% (21–38%) 30% (21–38%) 40% (31–50%)
intermediate 40 (19%) 60% (43–76%) 20% (8–32%) 34% (18–50%) 46% (29–32%)
Poor/very poorc 48 (23%) 49% (33–65%) 21% (8–33%) 28% (15–42%) 51% (36–66%)
Missing 14
Donor type: overall p value .7 .6 .9 .6
Sibling 74 (33%) 52% (39–65%) 25% (14–35%) 28% (18–39%) 47% (35–60%)
Unrelated 148 (67%) 52% (43–60%) 26% (19–33%) 32% (24–40%) 42% (34–50%)
Sex match: overall p value .2 .7 .2 .2
other combinations 176 (79%) 55% (47–63%) 24% (18–31%) 30% (22–37%) 46% (38–54%)
recipient-donor: m-f 46 (21%) 41% (25–57%) 28% (15–43%) 36% (22–50%) 36% (21–50%)
Conditioning intensity 0.1 0.6 0.2 0.3
Standard /Myelo-ablative 99 (45%) 55% (44–67%) 25% (15–34%) 25% (17–34%) 50% (40–61%)
Reduced intensity 123 (55%) 49% (39–58%) 27% (19–35%) 35% (26–44%) 38% (29–48%)
RBCTd (mediana): overall p value 12 (5–29) .6 .4 .9 .5
0–20 units 155 (70%) 52% (44–61%) 24% (17–31%) 32% (24–40%) 44% (36–52%)
>20 units 49 (22%) 51% (36–66%) 28% (15–41%) 29% (16–42%) 43% (29–57%)
Yes, but number not known 17 (8%) 46% (16–75%) 41% (12–70%) 21% (0–44%) 38% (8–67%)
Missing 1
Ferritine ng/ml (mediana):
overall p value
700 (261–1554) .09 .3 .3 .1
<1000 ng/ml 115 (58%) 57% (48–67%) 22% (14–30%) 27% (19–35%) 51% (42–61%)
>1000 ng/ml 81 (41%) 46% (35–58%) 28% (18–39%) 36% (25–47%) 36% (25–47%)
Missing 26
C-reactive protein (mediana):
overall p value
4.0 (2.2–10.1) .02 .1 .6 .4
Not elevated 146 (75%) 55% (47–64%) 22% (15–29%) 33% (25–41%) 45% (36–54%)
Elevated 49 (25%) 42% (27–56%) 33% (19–46%) 28% (15–42%) 39% (24–53%)
Missing 27
Chelation (yes): overall p value .6 .9 .9 .9
Yes 31 (31%) 44% (21–67%) 33% (13–53%) 34% (15–53%) 33% (13–54%)
No 70 (69%) 45% (33–57%) 29% (18–40%) 33% (22–44%) 38% (26–50%)
Missing 152
OS: Estimates of overall survival; NRM: non-relapse mortality; RI: relapse incidence and RFS: relapse-free survival at 3 years after HSCT, expressed as per-
centage with 95% confidence intervals. Differences between outcomes until 3 years after HSCT for subgroups were evaluated by the log-rank test (OS
and RFS) and the Gray test (RI and NRM); amedian (1st–3rd Qu); bmissing 1 patient; conly 9 patients had very poor cytogenetic characteristics; dnumber
of red blood cell transfusions (RBCT) prior to HSCT; ejust prior to conditioning HSCT. Therefore, poor and very poor risk groups are lumped together.
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intervals (CI) ranging from 36 to 44 months. OS, RFS,
NRM, and RI at 36 months were 52% (95% CI:
45–59%), 44% (95% CI: 37%–51%), 25% (95% CI:
19%–32%) and 31% (95% CI: 24%–37%), respectively.
Age had a significant impact on OS when analyzed as
continuous variable per decade (HR: 1.4, 95%CI:
1.1–1.8; p¼ .002), and on RFS (HR: 1.4, 1.1–1.8;
p¼ .002), but a borderline impact on NRM (HR: 1.4,
1.0–1.8; p¼ .05) and on relapse incidence (HR: 1.3,
1.0–1.7; p¼ .07). To evaluate the impact of WHO-classi-
fication on treatment outcome, patients were divided
in 4 subgroups: patients with 5% marrow blasts or
less at time of HSCT (RA, RARS, RCMD, RCMD-RS, 5q-),
patients with 6–19% marrow blasts (RAEB1 and
RAEB2), patients with 20–29% marrow blasts (AML-
MDS) and patients with CMML. The WHO classification
influenced significantly OS at 3 years (p¼ .002) (Table
1, Figure 1). Cytogenetics according to IPSS-R catego-
ries had no significant impact on treatment outcome.
However, the group with very poor-risk cytogenetics
could not be analyzed separately due to its small size
(n¼ 9) (Table 1). Only 11 patients were transplanted
with bone marrow as stem cell source, precluding an
analysis of the impact of stem cell source. Transfusion
burden (20 RBCT vs. >20 RBCT) did not have a sig-
nificant impact on any of the outcome parameters.
Ferritin levels (>1000 ng/ml) had a non-significant
negative impact on NRM and OS after HSCT, but ele-
vated CRP levels (>10mg/l) influenced OS signifi-
cantly (p¼ .02).
Correlations of potentially confounding factors for
the multivariable analyses
Patients with more than 5% bone marrow blasts
received a low number of red blood cell units (0–20
RBCT) before HSCT more frequently than patients with
less than 5% bone marrow blasts (p¼ .01), mainly
explained by a shorter duration of the interval between
diagnosis and HSCT in patients with more advanced
MDS according to WHO-classification (data not shown).
The number of RBCT before HSCT was not associated
with the cytogenetic risk category according to IPSS-R
(p¼ .7) nor with the interval between diagnosis and
actual HSCT of the whole cohort, including patients
with less than 5% marrow blasts (<6 vs. >6 months)
(p¼ .2). As expected, ferritin levels (>1000ng/ml vs.
<1000ng/ml) were influenced by a number of adminis-
tered RBCT prior to HSCT (p< .001). Ferritin levels,
measured as units of 1000mg/L were associated with
elevated CRP levels (p¼ .03) in this study. Co-
Figure 1. Overall survival according to WHO Categories. Kaplan–Meier plot for OS in the whole cohort, grouped by WHO catego-
ries. The corresponding 95% confidence intervals are indicated by the gray regions. The Log-rank p value is indicated.
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morbidities and intensity conditioning (MAC vs. RIC)
were significantly associated (p< .001).
Multivariable cox models
The basic model was restricted to the traditional varia-
bles indicating a potential prognostic impact, according
to the literature and the results from the univariable
analyses (Table 2). Therefore, only WHO-classification,
age at HSCT, donor type, sex-match, and intensity of
conditioning regimen were included in the model. We
added one by one the other variables of specific inter-
est in the current study: RBC transfusions, CRP levels,
ferritin levels (continuous in units of 1000ng/ml) and
comorbidities. This approach was necessary due to the
highly correlated nature of these variables. The transfu-
sion burden prior to HSCT influenced RFS significantly
(HR: 1.7; p¼ .02). The impact of pre-HSCT ferritin levels
was minor but significant on OS (HR: 1.2; p¼ .05) and
RI (HR: 1.3; p¼ .04). Presence of severe comorbidities
influenced OS after HSCT (HR: 1.8; p¼ .04). Elevated
CRP-levels (>10mg/L) had a borderline negative impact
on survival (HR: 1.6; p¼ .06).
Impact of iron chelation before HSCT on outcome
Thirty-one (14%) patients received iron chelation
prior to HSCT and ferritin levels at HSCT were avail-
able in 28 patients of them. The median duration of
chelation prior to HSCT was 4 months (range:
0–40 months). The median ferritin levels at HSCT was
1598 ng/ml, 9 chelated patients had ferritin levels
<1000 ng/ml at the time of HSCT. Sixteen chelated
patients had received >20 units of RBCT prior to
HSCT. The outcome of the patients chelated prior to
transplant conditioning was compared with a non-
chelated control group of 70 patients who had fer-
ritin levels >1000 ng/ml at HSCT or who had
received >20 units of RBCT prior to HCT condition-
ing. The overall 3-year survival in the chelated group
was 44% (21–67%) similar to the survival in the con-
trol group, 45% (33–57%, p¼ .6; Figure 2(A)). The
RFS, RI, and NRM were also similar in both groups:
33% (13–54%) in the chelated patients vs. 38%
(26–50%) in the non-chelated patients, 34%
(15–53%) vs. 33% (22–44%), and 32% (13–53%) vs.
29% (18–40%), respectively (Figure 2(B)).
Impact of phlebotomies or iron chelation after
HSCT on outcome
Twenty patients have been treated with phlebotomies
after HSCT. Most patients (80%) started phlebotomies
during the first year after HSCT. The median ferritin
levels before starting phlebotomies were: 3134 ng/ml
(range: 937–9985 ng/ml). The number of phlebotomies
was available in 16 patients: 9 patients underwent
<10 phlebotomies and 7 patients 10 or more
Table 2. Multivariate Cox models for assessment of the impact of relevant factors for all major outcomes.
OS HR (95% CI) (p) NRM HR (95% CI) (p) RI HR (95% CI) (p) RFS HR (95% CI) (p)
Basic model
Age (decades) 1.4 (1.1–1.7) (.01) 1.4 (1.0–2.0) (.04) 1.1 (0.8–1.4) (.73) 1.2 (1.0–1.5) (.09)
WHO classification
<5% marrow blastsa 1 1 1 1
RAEB/CMML 1.8 (1.0–3.2) (.05) 1.3 (0.7–2.6) (.4) 5.5 (2.0–15.3) (<.001) 2.4 (1.4–4.2) (<.001)
Transformed AML 3.0 (1.4–6.6) (<.001) 1.4 (0.5–4.6) (.5) 14.3 (4.4–47) (<.001) 4.6 (2.2–9.6) (<.001)
Patient-donor sex
Other combinations 1 1 1 1
Female donor into male recipient 1.2 (0.8–2.0) (.4) 1.3 (0.7–2.5) (.5) 1.2 (0.7–2.2) (.5) 1.3 (0.8–1.9) (.3)
Conditioning
Myeloablative 1 1 1 1
Reduced intensity 1.2 (0.8–1.9) (.3) 1.1 (0.6–2.0) (.7) 1.4 (0.8–2.3) (.2) 1.3 (0.9–1.8) (.3)
Added to basic model
Transfusions
RBCT 20 units 1 1 1 1
RBCT >20 units 1.5 (0.9–2.5) (.09) 1.7 (0.9–3.4) (.1) 1.8 (0.95–3.3) (.07) 1.7 (1.1–2.7) (.02)
C-reactive protein
CRP 10 1 1 1 1
CRP >10 1.6 (1.0–2.5) (.06) 1.5 (0.8–2.8) (.2) 0.8 (0.4–1.5) (.5) 1.1 (0.7–1.7) (.8)
Ferritin (units of 1000 ng/ml) 1.2 (1.0–1.4) (.05) 1.1 (0.8, 1.4) (.6) 1.3 (1.01–1.6) (.04) 1.2 (0.98–1.4) (.08)
Comorbidities
No 1 1 1 1
Mild/Moderate 0.9 (0.6–1.6) (.8) 1.1 (0.6–2.2) (.8) 0.7 (0.4–1.3) (.3) 0.9 (0.5–1.3) (.5)
Severe 1.8 (1.03–3.0) (.04) 2.0 (0.97–4.0) (.06) 1.4 (0.7–2.7) (.4) 1.6 (0.98–2.6) (.06)
OS: Estimates of overall survival; NRM: non-relapse mortality; RI: relapse incidence; RFS: relapse-free survival at 3 years after HSCT, expressed as percent-
age with 95% confidence intervals; HSCT: allogeneic hematopoietic stem cell transplantation; RBCT: red blood cell transfusion; CRP: C-reactive protein.
aIncluding RA/RARS/del5q/RCMD(RS); Patients with missing data for a variable were excluded from the models where this variable was analyzed.
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phlebotomies. The ferritin levels decreased to levels
<1000 ng/ml in 10 out of 19 patients at the time of
completion of phlebotomies or at 24 months after
HSCT and decreased more than 50% in five additional
patients. In the remaining 5 patients, the effect was
not evaluable mainly due to insufficient follow-up
after starting phlebotomies.
Sixteen patients have received iron chelation (defera-
sirox only) after HSCT. Nine patients started chelators
during the first 6 months after HSCT and 13 patients
during the first year after HSCT. The median interval
between HSCT and starting chelation was 5 months
(range: 1–18). The median ferritin level before starting
chelation was: 3122ng/ml (range: 69–9040ng/ml). The
median duration of iron chelation was 4 months (range:
0.5–40 months). The ferritin levels decreased to levels
<1000ng/ml in 3 out of 16 patients during iron chela-
tion and decreased more than 50% in four additional
patients. In the remaining patients, the effect was not
evaluable due to missing ferritin levels (5 patients) or
too short duration of chelation (7 patients). The median
duration of iron chelation in the 5 responding patients
was 4 months (range: 1.5–7 months).
We combined the data of both interventions,
because the number of patients who were treated
with either chelation or phlebotomies was relatively
small, and both interventions are aiming at reducing
the iron overload. Fourteen patients started treatment
with either phlebotomies or chelation during the first
6 months after HSCT, and 27 patients started these
interventions within the first 12 months after HSCT.
The outcome of the patients treated with iron reduc-
tive interventions was compared with the untreated
control groups with ferritin levels >1000 ng/ml alive
and relapse-free at the landmarks of 6, 12 and
24 months, respectively (Tables 3 and 4). Only patients
Figure 2. Overall survival (A) and relapse-free survival (RFS) according to iron reduction therapy prior to Transplantation (B).
Kaplan–Meier plot for OS (A) and RFS (B) in patients who either received chelation therapy or could have received chelation ther-
apy based on their increased ferritin levels or received transfusions, prior to transplant. The corresponding 95% confidence inter-
vals are indicated by the gray regions.
Table 3. Outcome of patients with iron reduction treatment after HSCT.
Start iron reduction
treatment after HSCT
Iron reduction
after HSCT
Landmark after HSCT (months)
0–6 6–12 12–24
Nr of patientsa No 101 77 51
Yes 12 27 21
OSb No 65% (54–75%) 0.08 75% (65–86%) 0.3 85% (79–98%) 0.9
Yes 90% (71–100%) 81% (61–100%) 88% (73–100%)
RFSb No 56 (46–67%) 0.04 67% (55–79%) 0.3 81% (69–93%) 0.5
Yes 90% (71–100%) 57% (58–98%) 88% (74–100%)
RIb No 26 %(17–35%) 0.19 18% (8–27%) 0.8 7% (0–16%) 0.6
Yes 10% (0–29%) 22% (2–42%) 12% (0–26%)
NRMb No 18% (10–26%) 0.13 15% (6–24%) 0.08 12% (2–21%) 0.14
Yes 0% (0–0%) 0% (0–0%) 0% (0–0%)
OS: estimates of overall survival; RFS: relapse-free survival at 3 years; RI: relapse incidence; NRM: non-relapse mortality; and after HSCT,
expressed as percentage with 95% confidence intervals; HSCT: allogeneic hematopoietic stem cell transplantation.
aControl group: patients with ferritin levels above 1000 ng/ml at the start of comparison.
bEstimates of outcomes at 3 years after HSCT (95% confidence intervals) with p values of log-rank test/Gray test of non-treated vs. treated
groups. The outcomes are measured from the three landmark points (6, 12, and 24 months after HSCT).
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who received iron reductive therapy within 6 months
after HSCT had a significantly improved 3-year RFS
compared to the non-treated patient population (90%
(71–100%) vs. 56% (46–67%); p¼ .04 Figure 3, Tables 3
and 4). The survival at this landmark analysis was
reduced compared to the control group with a 3-year
OS of 90% (71–100%) vs. 65% (54–75%) in the control
group (Tables 3 and 4). The outcomes at later land-
mark analyses did not indicate relevant differences
with the exception of a moderate difference of the
NRM at both landmarks (Tables 3 and 4).
Discussion
Allogeneic hematopoietic stem cell transplantation
(HSCT) is considered the most potent curative
option in myelodysplastic syndromes (MDS). Many
retrospective analyses evaluated relevant prognostic
parameters, to enable adequate patient selection for
treatment [16,17] and reviewed in [18]. This large pro-
spective observational study collected detailed infor-
mation on several relevant prognostic factors,
including relevant patient characteristics, disease
modalities, transfusion data, and iron parameters in
Table 4. Landmark population: alive and relapse free.
0–6 m 0–12 m 0–24 m
Start iron reduction treatment No Yes No Yes No Yes
N(%) N(%) N (%) N (%) N(%) N%
Total N 101 12 77 22 51 21
WHO
RA/RARS/RCMD-RS/5q- 31 (31) 3 (25) 24 (31) 5 (23) 18 (35) 6 (29)
RAEB/CMML 64 (63) 8 (67) 48 (62) 16 (73) 31 (61) 14 (67)
RAEB-t/sAL 6 (6) 1 (8) 5 (6) 1 (5) 2 (4) 1 (5)
Transfusions
Yes, nr missing 7 (7) 0 (0) 4 (5) 1 (5) 4 (8) 0 (0)
Nr <¼20 70 (69) 8 (67) 54 (70) 16 (73) 34 (67) 16 (76)
Nr >20 24 (24) 4 (33) 19 (25) 5 (23) 13 (25) 5 (24)
Comorbidities
No comorbidity 52 (51) 6 (50) 42 (55) 12 (55) 26 (51) 10 (48)
Mild/moderate 31 (31) 5 (42) 24 (31) 6 (27) 17 (33) 8 (38)
Severe 18 (18) 1 (8) 11 (14) 4 (18) 8 (16) 3 (14)
cGvHD before landmark
No 54 (54) 7 (58) 25 (33) 6 (27) 11 (22) 3 (14)
Limited 34 (34) 4 (33) 39 (51) 10 (45) 30 (60) 12 (57)
Extensive 12 (12) 1 (8) 12 (16) 6 (27) 9 (18) 6 (29)
Missing 1 1 1
cGvHD: chronic graft versus host disease. Table describing relevant characteristics of both groups at 6, 12 and 24 months.
cGvHD: chronic graft versus host disease.
Figure 3. Overall survival and relapse-free survival of patients alive and relapse-free at 6 months after transplantation, stratified in
2 groups according to iron reduction therapy given during the first 6 months after transplantation or not. Landmarked
Kaplan–Meier plot for OS and RFS in patients who either received iron reduction therapy or could have received iron reduction
therapy based on their increased ferritin levels or received transfusions. Patients were selected based on ferritin levels >1000 ng/
ml. The landmark time-point is indicated by the vertical dashed line. Only patients alive and relapse-free at 6 months are
included. The corresponding 95% confidence intervals are indicated by the gray regions.
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patients with MDS undergoing HSCT. The overall out-
come of this study, and especially the NRM of 25%
(95% CI: 19%–32%) at 36 months, compares favorably
with other recently published studies [4,6,10] despite
the high mean age of 59 years in this study. Age, BM
blast percentage, and comorbidity at time of HSCT
had a significant influence on outcome after HSCT.
The overall outcome of this study, and especially the
NRM at 36 months, compares favorably with other
recently published studies reflecting the data of this
study showed that intensity of conditioning regimen
had no impact on overall survival, confirming several
other retrospective studies [5,6,19,20].
The primary objective of this study was to study
the impact of iron overload and iron toxicity on out-
come after HSCT. As expected [21], the data showed
a significant association between transfusion burden
and ferritin levels (p< .001). A high RBCT burden,
higher than 20 units prior to transplantation, was
significantly associated with a decreased relapse-free
survival (HR: 1.7; p¼ .02). Although it is difficult to
separate the impact of transfusion load as an inde-
pendent prognostic marker from the progression of
bone marrow failure and increased tumor burden in
nontransplanted MDS patients, several studies
showed a significant impact of transfusion burden
on outcome after HSCT [17,22,23], including our own
retrospective study [24]. In this study, the impact of
high transfusion burden on overall survival was less
explicit (HR: 1.5; p¼ .09), in contrast to the signifi-
cantly reduced RFS, which can be explained by the
smoldering nature of less advanced MDS patients in
this cohort (only 16 patients had AML-MDS at time
of transplantation). This selection may be associated
with a prolonged survival after relapse.
Ferritin is an acute-phase protein, and therefore
also elevated in case of infection, inflammation or
high tumor burden [25]. To correct for this con-
founding factor we analyzed CRP levels, another
acute phase protein, which was significantly corre-
lated with ferritin levels. Both ferritin levels and ele-
vated CRP levels had an impact on overall survival,
but only ferritin levels had a significant impact on
relapse incidence reflecting its association with more
advanced MDS stages. Therefore, the impact of ele-
vated CRP levels on NRM was more pronounced
compared to the impact of elevated ferritin levels,
confirming data from a large HSCT study in AML and
MDS [26]. Ferritin levels are sometimes used as a
marker of transfusion burden [27], but in the multi-
variable analysis of that study, only co-morbidities
and percentage of marrow blasts at time of HSCT
predicted OS [27]. Therefore, it has been postulated
that transferrin saturation, NTBI, and LPI are better
parameters to monitor and to study iron toxicity dur-
ing conditioning for HSCT and the first two weeks
after HSCT [28]. When transferrin saturation exceeds
85%, species of non-transferrin-bound iron (NTBI),
and its redox active component labile plasma iron
(LPI), become detectable in the plasma [29,30].
Transferrin becomes saturated immediately during
transplant conditioning and remains elevated until
engraftment [30]. These redox active components
lead in various steps to associated tissue damage,
mostly cardiac, endocrine and liver tissue, and may
also affect clonal evolution in MDS [31]. Reduction of
iron stores, may alleviate long-term effects of iron
toxicity in transfusion-dependent patients with MDS
[32]. Consensus statements advice to administer iron
chelation therapy in those patients with an expected
long-term survival [33,34]. In high-risk MDS, patients
may not live long enough after HSCT to be exposed
to the prolonged toxic effects of transfusional ther-
apy. Studies the impact of iron chelation in a trans-
plant setting is ongoing [35].
In the current study, we were able to investigate
the impact of iron reduction therapy on outcome after
HSCT. It is important to realize that both high ferritin
levels and high transfusion burden were associated
with an inferior outcome in this study. Both the che-
lated and its control group were selected based on
these two poor prognostic factors. Iron overload in
the transplant setting may be reduced both by iron
chelation therapy [36,37] and by phlebotomies [38].
Administration of iron chelation therapy prior to HSCT
had no influence on treatment outcome in this study.
However, the ferritin levels of the chelated patients at
HSCT were still elevated with a median level of
1772 ng/ml, and only 8 out the 28 chelated patients
with available ferritin levels had ferritin levels
<1000 ng/ml at HSCT. This indicates that the duration
of iron chelation was insufficient in the majority of
cases, probably reflecting the short period of iron che-
lation prior to HSCT in this study. More efficient iron
chelation prior to HSCT may be achieved by earlier
iron reduction prior to the transplant procedure and/
or by more vigorous iron chelation using higher dos-
ages of chelators in the immediate pre-transplant set-
ting [33,35].
Patients with MDS may also receive iron reduction
interventions to reduce iron overload after HSCT [39].
We were able to evaluate the influence of iron reduc-
tion therapy after HSCT in a subgroup of 35 patients,
consisting of iron chelation in 16 patients and/or
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phlebotomies in 20 patients (one patient received bot
phlebotomies and iron chelation). Iron reduction by
phlebotomies started within one year after HSCT in
80% and by iron chelation in 81% of the patients
receiving the respective therapies. The efficacy of
reducing ferritin levels by phlebotomies was excellent
with more than 50% reduction in 74% of the patients
and 28% after chelation, probably reflecting the short
period of chelation (median 4 months). Most events
(relapse or death by any cause) occurred within the
6 months after transplantation in our study. Therefore,
iron reduction therapy is expected to have more
impact on the outcome, if initiated within 6 months
after HSCT, as shown in our study. The patient popula-
tion who received iron chelation therapy or phleboto-
mies within 6 months after HSCT had a significantly
improved RFS compared to the non-chelated patient
population with ferritin levels >1000 ng/ml or having
received transfusions before HSCT (p¼ .04), while
the OS at this landmark was moderately (p¼ .08)
improved. Selection of the patients for either of the
interventions cannot be ruled out, but the data in the
supplementary table do not show remarkable differen-
ces in both groups.
In conclusion, analysis of this non-interventional
prospective data from MDS patients, not pretreated
with intensive chemotherapy before undergoing allo-
geneic HSCT, demonstrated that transfusion burden
prior to HSCT influenced progression-free survival,
without a significant effect on survival. Relapse-free
survival may be predicted by serum ferritin levels, in
contrast to CRP levels, but this effect may reflect the
association with tumor burden rather than iron over-
load. Administration of iron reduction prior to HSCT
had no impact on the primary outcome, but iron
reduction therapy after HSCT increased relapse-free
survival, if initiated within 6–12 months after HSCT.
The predictive value of the transfusion burden prior to
HSCT may be less relevant in patients with more
advanced disease stages due to dominant effect of
the disease stage on outcome after HSCT.
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